CEMIP2: A Potential Drug Target and Biomarker for Cell Surface Hyaluronidase (ISOFORM A)

Target Name: CEMIP2

NCBI ID: G23670

CEMIP2

CEMIP2: A Potential Drug Target and Biomarker for Cell Surface Hyaluronidase (ISOFORM A)

Hyaluronidase (ISOFORM A) is a cell surface enzyme that is involved in the production of hyaluronic acid, a component of connective tissue extracellular matrix (ECM). Hyaluronic acid plays a crucial role in maintaining tissue hydration, providing a scaffold for cell migration and promoting tissue repair. The function of hyaluronidase (ISOFORM A) is essential for maintaining the extracellular environment of cells, and dysregulation of this enzyme has been implicated in a variety of diseases, including cancer, inflammation, and autoimmune disorders.

CEMIP2 (Cell Surface Hyaluronidase (ISOFORM A)) is a protein that is expressed in various cell types, including epithelial, endothelial, and stromal cells. It is a 21-kDa glycoprotein that consists of a N-terminal cytoplasmic domain, a transmembrane region , and an C-terminal extracellular domain. CEMIP2 is responsible for the production of hyaluronic acid from hyaluronan (a disaccharide consisting of a hyaluronate unit and a galactose unit).

CEMIP2 is a potential drug target for several reasons. First, CEMIP2 is a widely expressed protein, which means that it is likely to be a good candidate for targeting with small molecules or antibodies. Second, CEMIP2 is involved in the production of a critical component of the extracellular matrix, which makes it an attractive target for diseases that are characterized by disrupted ECM. Finally, CEMIP2 is involved in several cellular processes that are important for tissue homeostasis, including cell migration, invasion, and angiogenesis.

Several studies have suggested that targeting CEMIP2 may be a useful strategy for treating various diseases. For example, overexpression of CEMIP2 has been shown to promote the development of cancer cells, and inhibition of CEMIP2 has been shown to inhibit the growth of cancer cells. Additionally , overexpression of CEMIP2 has been shown to contribute to the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Another potential mechanism by which CEMIP2 may contribute to disease is by modifying the extracellular matrix. The production of hyaluronic acid by CEMIP2 is critical for maintaining the extracellular environment of cells, and alterations in the levels or composition of hyaluronic acid have been implicated in a variety of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

In conclusion, CEMIP2 is a protein that is involved in the production of hyaluronic acid, a critical component of the extracellular matrix. CEMIP2 is a potential drug target for several diseases, including cancer, inflammation, and autoimmune disorders. Further research is needed to fully understand the role of CEMIP2 in these diseases and to develop effective treatments.

Protein Name: Cell Migration Inducing Hyaluronidase 2

Functions: Cell surface hyaluronidase that mediates the initial cleavage of extracellular high-molecular-weight hyaluronan into intermediate-size hyaluronan of approximately 5 kDa fragments (PubMed:28246172). Acts as a regulator of angiogenesis and heart morphogenesis by mediating degradation of extracellular hyaluronan, thereby regulating VEGF signaling (By similarity). Is very specific to hyaluronan; not able to cleave chondroitin sulfate or dermatan sulfate (PubMed:28246172)

The "CEMIP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEMIP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets